The Wall Street Journal: FDA may OK COVID boosters for 16- and 17-year-olds as soon as next week

The Food and Drug Administration could authorize COVID-19 boosters from Pfizer Inc.
PFE,
-2.96%
 and BioNTech SE
BNTX,
+4.17%
 for use in 16- and 17-year-olds as soon as next week as concerns rise over a new, possibly more transmissible variant, according to a person familiar with the planning.

The agency is planning to move rapidly to take action on a request by the companies to authorize boosters for 16- and-17-year-olds, according to a person familiar with the matter. So far, only people 18 years and older are eligible for boosters.

This post was originally published on Market Watch